Medical Cannabis for ADHD UK: What Patients Need to Know

Attention Deficit Hyperactivity Disorder (ADHD) is now one of the fastest-growing categories of patients seeking medical cannabis in the UK. A significant increase in referrals from adults with ADHD — many of whom have struggled with stimulant medications such as methylphenidate or amphetamines — has been reported by clinics including Releaf, Alternaleaf and Lyphe.

Research from King's College London published in late 2025 found that adult ADHD patients using prescribed cannabis-based medicine reported meaningful improvements in attention, impulsivity control, and sleep quality, with a favourable side effect profile compared to traditional stimulants in a subset of treatment-resistant cases.

Why ADHD Patients Are Seeking Cannabis Treatment

Traditional ADHD treatments — primarily stimulant medications such as Ritalin (methylphenidate) and Concerta — are effective for many patients but come with significant drawbacks for others. Common complaints include appetite suppression, cardiovascular side effects, mood crashes as medication wears off, sleep disruption, and difficulty with creative or open-ended tasks.

Cannabis-based medicines — particularly CBD-dominant and balanced THC:CBD formulations — are being explored as an alternative for patients who have failed two or more conventional ADHD treatments, which is the standard qualifying threshold for UK cannabis prescribing.

What the Evidence Says

Evidence for cannabis and ADHD remains at an early stage, but several studies point to potential benefits. A 2025 UK observational study found that 61% of ADHD patients reported improved concentration after three months of cannabis-based treatment, with CBD-dominant products performing particularly well. The CBME ADHD Registry, tracking outcomes for 1,400 UK patients, reports reduced hyperactivity and improved sleep in approximately 55% of subjects at 12 months.

It is important to note that cannabis prescribing for ADHD in the UK is off-label — there is no NICE-approved cannabis-based medicine specifically for ADHD. Prescriptions are issued on a specialist's clinical judgement where conventional treatments have been inadequate.

How to Access Medical Cannabis for ADHD in the UK

To qualify for medical cannabis for ADHD, patients typically need a confirmed ADHD diagnosis, evidence of having tried at least two conventional ADHD treatments, and a referral or self-referral to a GMC-registered cannabis specialist. Clinics known for ADHD prescribing include Lyphe, Releaf, and Mamedica. Use our clinic directory to compare options and wait times.

Online consultations are available from all major UK cannabis clinics — no travel required. Initial consultations typically take 30-60 minutes and involve a review of your ADHD history and previous treatment record.

ADHD, University Students and the UK Cannabis System

A notable trend observed at UK clinics is an increase in referrals from university-age patients. Many have received ADHD diagnoses during or after university, face long NHS waiting lists for stimulant medication, and are turning to private cannabis prescribing as a faster route to treatment. Medical cannabis is legal with a valid prescription — students can use their prescribed medication on campus, though university-specific policies vary.

Key Considerations

Cannabis-based medicine for ADHD is not suitable for everyone. Prescribing for patients under 25 is approached with additional caution due to the developing brain's sensitivity to THC. Patients with a personal or family history of psychosis should discuss this explicitly with their specialist. Cannabis can interact with common ADHD medications — see our drug interactions guide. UK law also prohibits driving with THC above the legal limit in blood, regardless of whether it is prescribed. See our medical cannabis and driving guide.